The HIFU growth story is intact and accelerating, but the company is burning cash rapidly ($5.4M in Q1 alone, leaving only $15M). With a $135M market cap and no path to near-term profitability, the stock will likely remain range-bound until either (a) the company demonstrates operating leverage or (b) announces a capital raise. Watch for the June 1 Investor Day for any strategic updates.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 7 $4.16entry
- T+1 · 6mo ago −0.72%α −1.55% · $4.13
- T+5 · 6mo ago 0.00%α −1.50% · $4.16
- T+20 · 6mo ago +12.74%α +9.60% · $4.69
- T+60 · due 4mo ago Pending
Price Chart
How similar events traded
Executive Summary
EDAP reported Q1 2026 total revenue of $17.8M (up 25% YoY from $14.3M), driven by record HIFU revenue of $11.6M (+78% YoY). However, the net loss widened to $9.1M (-$0.24/share) from $7.4M (-$0.20/share) a year ago, and the company reiterated (not raised) its 2026 guidance. The HIFU business is accelerating, but the company remains deeply unprofitable with negative operating cash flow and a rapidly shrinking cash balance.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $17.8M vs $14.3M YoY (+25%)
- HIFU revenue $11.6M, up 78% YoY, record quarter
- 11 Focal One systems sold vs 6 YoY (+83%)
- U.S. Focal One procedures up 53% YoY
- Gross margin improved to 45.7% from 42.0% YoY
- Net loss widened to $9.1M (-$0.24/share) from $7.4M (-$0.20/share)
- Operating loss $7.4M vs $6.3M YoY
- Cash burn continues: cash dropped to $15.0M from $20.5M in 3 months
- 2026 guidance reiterated (not raised): HIFU $50-54M, total $72-80M
- HIFI-2 study published in European Urology Oncology, positive salvage HIFU data
Financial Impact
HIFU revenue growth of 78% YoY to $11.6M is the key positive; net loss of $9.1M and cash burn of $5.4M in the quarter are the key negatives
Risk Factors
- Cash burn: $15M cash at March 31 vs $20.5M at Dec 31, less than 3 quarters of runway at current burn rate
- No EPS or revenue consensus beat, EPS miss vs Street estimates
- Guidance reiterated, not raised, despite strong Q1, suggests management sees H2 headwinds
- Non-core ESWL/Distribution revenue declining ($6.2M vs $7.8M YoY) as company pivots to HIFU
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003113 |
| Document: f8k_050726.htm | 0001171843-26-003113 |
| Document: 0001171843-26-003113-index-headers.html | 0001171843-26-003113 |
| Document: 0001171843-26-003113-index.html | 0001171843-26-003113 |
| Document: 0001171843-26-003113.txt | 0001171843-26-003113 |
| 8-K Data (Synthetic) | 0001171843-26-003113 |
Track record
12 reports on EDAP
The track record builds as more bullish or bearish reports settle.
Filters
- Aug 17, 202613w ago Insider Cluster Mixed 5/10 No price data
- May 29, 202624w ago 8-K Neutral 4/10 Entry $4.32 to $5.10 ▲ +18.06% +19.85% vs SPY
- May 14, 202626w ago DEFA14A Bearish 6/10 Entry $4.13 to $4.77 ▼ −15.50% −16.35% vs SPY
- May 14, 202626w ago DEFA14A Neutral 3/10 Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
- May 14, 202626w ago Press Release Neutral 3/10 Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Viewing Entry $4.16 to $4.69 ▲ +12.74% +9.60% vs SPY
- Apr 16, 202630w ago Press Release Neutral 1/10 Entry $3.59 to $4.16 ▲ +15.88% +10.06% vs SPY
- Apr 1, 202632w ago EFFECT Neutral 4/10 Entry $3.53 to $3.31 ▼ −6.23% −15.95% vs SPY
- Mar 26, 202633w ago S-3/A Neutral 4/10 Entry $3.73 to $3.22 ▼ −13.67% −26.41% vs SPY
- Mar 25, 202633w ago S-3 Neutral 5/10 Entry $3.77 to $3.22 ▼ −14.59% −25.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers